<DOC>
	<DOC>NCT01802866</DOC>
	<brief_summary>The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of progression of geographic atrophy compared to placebo in subjects with dry age-related macular degeneration.</brief_summary>
	<brief_title>Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>1. Males or females, age â‰¥55 years. 2. Clinical diagnosis of GA associated with AMD 3. Able and willing to provide written informed consent. 4. Able to reliably administer oral medication by self or with available assistance. 1. Active CNV or presence of an active ocular disease. 2. Known serious allergy to the fluorescein sodium for injection in angiography. 3. Prespecified laboratory abnormalities at screening. 4. Treatment with any investigational study drug within 30 days of screening or device (within 60 days of screening) 5. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding 6. Female subjects who are pregnant or lactating. 7. Female subjects of childbearing potential and male subjects who are not surgically sterile who are not willing to practice a medically accepted method of birth control from screening through 30 days after completion of the study. 8. Unstable or poorly controlled medical or ophthalmic conditions</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Geographic atrophy</keyword>
	<keyword>GA</keyword>
	<keyword>Dry AMD</keyword>
</DOC>